Company intelligence / Profile preview
LadRx
Los Angeles, California, United Statesladrxcorp.com ↗
- Ownership
- Public · LADX
- Development stage
- Preclinical
01
Overview
LadRx’s lead clinical asset was aldoxorubicin—a rationally engineered cytotoxic that delivers doxorubicin directly to tumors using albumin-binding. Aldoxorubicin has shown lower cardiotoxicity and promising efficacy in Phase II trials for advanced soft tissue sarcoma. The company’s next-generation candidate LADR‑7 has been manufactured under GMP and aims for IND filing in late 2024. The company previously outlicensed assets like arimoclomol and aldoxorubicin but recently regained rights to aldoxorubicin after terminating its license with ImmunityBio.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
ImmunityBio/NantCell Inc. (previous licensee of aldoxorubicin; agreement now terminated)Orphazyme A/S/Zevra Inc. (arimoclomol licensee—royalty/milestone rights transferred to XOMA Corp.)XOMA Corporation (holds royalty/milestone rights on certain assets)
04
Financials
- Market cap
- $5.4K
- Total revenue
- $0
- Enterprise value
- $-201.5K
Beyond the preview
Go deeper on LadRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LadRx.